A decrease in the prognostic nutritional index is associated with a worse long-term outcome in gastric cancer patients undergoing neoadjuvant chemotherapy

A decrease in the prognostic nutritional index is associated with a worse long-term outcome in gastric cancer patients undergoing neoadjuvant chemotherapy
复制标题

DOI:
10.1007/s00595-017-1469-y
复制
发表时间:
2017-08-01
期刊:
影响因子:
2.5
通讯作者:
Kanehiro, Hiromichi
Kanehiro, Hiromichi
中科院分区:
医学4区
文献类型:
--
作者:
Migita, Kazuhiro;Matsumoto, Sohei;Kanehiro, Hiromichi

文献摘要

被引文献

相似文献

本研究的目的是评估预后营养指数(PNI)对胃癌新辅助化疗(NAC)患者预后的影响。本研究回顾了54例接受NAC和R0胃切除术的胃癌患者。NAC开始前和胃切除术前的PNI采用以下公式计算:10 ×血清白蛋白(g/dl) + 0.005 ×总淋巴细胞计数(每mm(3))。进行多变量分析以确定总生存期(OS)的预测因素。术前nac和术前PNI均值分别为48.3 +/- 5.1和48.2 +/- 4.7 (p = 0.934)。31例(57.4%)患者NAC后PNI下降。nac前PNI和术前PNI与OS率无显著相关。PNI值降低患者的3年OS率明显低于PNI值维持或升高的患者(41 vs. 76.4%, p = 0.003)。多变量分析显示,PNI值降低是不良OS的独立预测因子(p = 0.006)。在接受NAC的胃癌患者中,PNI值降低与较差的长期预后相关。
The aim of this study was to evaluate the prognostic impact of the prognostic nutritional index (PNI) in gastric cancer patients undergoing neoadjuvant chemotherapy (NAC).This study reviewed 54 patients with gastric cancer who underwent NAC and a subsequent R0 gastrectomy. The PNI before starting NAC and before gastrectomy were calculated using the following formula: 10 x serum albumin (g/dl) + 0.005 x total lymphocyte count (per mm(3)). A multivariate analysis was performed to identify the predictors of overall survival (OS).The mean pre-NAC and preoperative PNI were 48.3 +/- 5.1 and 48.2 +/- 4.7, respectively (p = 0.934). The PNI decreased after NAC in 31 patients (57.4%). The pre-NAC PNI and preoperative PNI were not significantly associated with the OS rate. The 3-year OS rate in patients with the decreased PNI values was significantly lower than that in the patients whose PNI values were either maintained or increased (41 vs. 76.4%, p = 0.003). A multivariate analysis revealed that a decreased PNI value was an independent predictor of a poor OS (p = 0.006).Decreased PNI values were associated with worse long-term outcomes in gastric cancer patients undergoing NAC.